Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NATIENS: Etanercept for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
NCT02987257Phase 3Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- Mar 2023
- Primary completion
- Oct 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) comparing Harmonized supportive care + Placebo with Harmonized supportive care + Etanercept (2 arms). Primary endpoint: Time to complete re-epithelialization up to 4 weeks. Started Mar 2023; status: completed.
02
Drugs
etanercept
03
Conditions
Stevens-Johnson syndrome (SJS)toxic epidermal necrolysis (TEN)
Beyond the preview
Go deeper on NCT02987257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02987257.